Zymeworks, Inc. (ZYME)
25.15
-0.81
(-3.12%)
USD |
NASDAQ |
Oct 02, 16:00
25.01
-0.14
(-0.56%)
After-Hours: 20:00
Zymeworks Enterprise Value : 1.808B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.808B |
| October 01, 2026 | 1.866B |
| September 30, 2026 | 1.904B |
| September 29, 2026 | 1.955B |
| September 28, 2026 | 1.950B |
| September 25, 2026 | 1.906B |
| September 24, 2026 | 1.927B |
| September 23, 2026 | 1.977B |
| September 22, 2026 | 1.982B |
| September 21, 2026 | 1.927B |
| September 18, 2026 | 1.910B |
| September 17, 2026 | 1.975B |
| September 16, 2026 | 1.886B |
| September 15, 2026 | 1.873B |
| September 14, 2026 | 1.930B |
| September 11, 2026 | 1.886B |
| September 10, 2026 | 1.900B |
| September 09, 2026 | 1.952B |
| September 08, 2026 | 2.021B |
| September 04, 2026 | 2.099B |
| September 03, 2026 | 2.150B |
| September 02, 2026 | 2.232B |
| September 01, 2026 | 2.133B |
| August 31, 2026 | 2.114B |
| August 28, 2026 | 2.032B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.086B |
| August 26, 2026 | 2.107B |
| August 25, 2026 | 1.975B |
| August 24, 2026 | 2.068B |
| August 21, 2026 | 2.061B |
| August 20, 2026 | 1.910B |
| August 19, 2026 | 1.956B |
| August 18, 2026 | 1.874B |
| August 17, 2026 | 1.819B |
| August 14, 2026 | 1.806B |
| August 13, 2026 | 1.852B |
| August 12, 2026 | 1.792B |
| August 11, 2026 | 1.748B |
| August 10, 2026 | 1.737B |
| August 07, 2026 | 1.692B |
| August 06, 2026 | 1.662B |
| August 05, 2026 | 1.689B |
| August 04, 2026 | 1.638B |
| August 03, 2026 | 1.567B |
| July 31, 2026 | 1.577B |
| July 30, 2026 | 1.632B |
| July 29, 2026 | 1.582B |
| July 28, 2026 | 1.625B |
| July 27, 2026 | 1.653B |
| July 24, 2026 | 1.643B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 528.72B |
| Aprea Therapeutics, Inc. | -31.89M |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Savara, Inc. | 845.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.02M |
| Revenue (Quarterly) | 4.59M |
| Total Expenses (Quarterly) | 49.61M |
| EPS Diluted (Quarterly) | -0.6168 |
| Gross Profit Margin (Quarterly) | 57.43% |
| Profit Margin (Quarterly) | -980.8% |
| Earnings Yield | -8.01% |
| Normalized Earnings Yield | -7.998 |